MARKET

CYCN

CYCN

Cyclerion Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.200
+0.120
+3.90%
After Hours: 3.200 0 0.00% 16:58 12/04 EST
OPEN
3.110
PREV CLOSE
3.080
HIGH
3.210
LOW
3.070
VOLUME
339.81K
TURNOVER
--
52 WEEK HIGH
8.96
52 WEEK LOW
1.780
MARKET CAP
108.68M
P/E (TTM)
-1.0768
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Is Cyclerion Therapeutics, Inc. (CYCN) A Good Stock To Buy?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
Insider Monkey · 2d ago
Andreas Busch Is The Chief Innovation Officer of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) And They Just Picked Up 96% More Shares
Investors who take an interest in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) should definitely note that the Chief...
Simply Wall St. · 11/15 12:55
CSCO, NIO, DKNG and VIPS among premarket gainers
Urovant Sciences (UROV) +93% as Sumitovant Biopharma to acquire balance shares for $16.25/share.CBAK Energy Technology (CBAT) +55%.Hall of Fame Resort & Entertainment (HOFV) +37% after providing update on the Inaugural NFL Alumni Academy.Li Auto (LI) +29% on
Seekingalpha · 11/13 13:27
The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12)
Benzinga · 11/13 12:40
The Week Ahead In Biotech: Spectrum Pharma FDA Decision, Biogen And Abbott Earnings, Cancer Conference
Biopharma stocks, which started the week on a firm footing, lost momentum mid-way through amid market-wide sell-off triggered by waning stimulus hopes.
Benzinga · 10/18 16:50
PGEN, GME, APHA and FSLY among midday movers
Gainers: Staffing 360 Solutions (STAF) +86%.China HGS Real Estate (HGSH) +65%.Huttig Building Products (HBP) +39%.Dragon Victory International (LYL) +35%.SPI Energy (SPI) +30%.Organogenesis (ORGO) +20%.Armata Pharmaceuticals (ARMP) +20%.Cars.com (CARS) +18%.Precigen (PGEN) +17%.GameStop (GME) +16%.Losers: Kaixin Auto
Seekingalpha · 10/15 16:47
Organogenesis Holdings, Anavex Life Sciences leads healthcare gainers; Vertex Pharmaceuticals, Aphria among major losers
Gainers: Organogenesis Holdings (ORGO) +22%, Anavex Life Sciences (AVXL) +16%, Precigen (PGEN) +12%, Replimune Group (REPL) +11%, Armata Pharmaceuticals (ARMP) +11%.Losers: Vertex Pharmaceuticals (VRTX) -20%, Aphria (APHA) -16%, Cyclerion Therapeutics (CYCN) -13%, Liquidia Technologies (LQDA) -9%, Arvinas (ARVN) -7%.
Seekingalpha · 10/15 15:12
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Allscripts Healthcare Solutions Shares Jump
Toward the end of trading Wednesday, the Dow traded down 0.45% to 28550.31 while the NASDAQ fell 0.75% to 11775.45. The S&P also fell, dropping 0.56% to 3,492.39.
Benzinga · 10/14 18:33
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CYCN. Analyze the recent business situations of Cyclerion Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CYCN stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 142
Institutional Holdings: 23.07M
% Owned: 67.94%
Shares Outstanding: 33.96M
TypeInstitutionsShares
Increased
20
6.09M
New
20
-458.83K
Decreased
25
390.86K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Marsha Fanucci
President/Chief Scientific Officer
Mark Currie
Chief Executive Officer/Director
Peter Hecht
Chief Financial Officer
William Huyett
Other
Andreas Busch
Independent Director
Kevin Churchwell
Independent Director
George Conrades
Independent Director
Ole Isacson
Independent Director
Stephanie Lovell
Independent Director
Terrance McGuire
Independent Director
Michael Mendelsohn
Independent Director
Amy Schulman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CYCN
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for serious and orphan diseases. The Company develops guanylate cyclase (sGC) stimulators. The Company’s portfolio includes five sGC stimulator programs: olinciguat, praliciguat, IW-6463 and two organ-targeted programs. Olinciguat is an oral, once-daily vascular sGC stimulator for patients suffering from sickle cell disease. Olinciguat is in Phase II trial. Praliciguat is an oral, once-daily systemic sGC stimulator for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy. Praliciguat is in two separate Phase II trials. IW-6463 is a central nervous system-penetrant oral sGC stimulator. IW-6463 is in a Phase I and is designed to treat serious and orphan neurodegenerative diseases. Its two organ-targeted programs are designed to address serious and orphan diseases of the liver and lung.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cyclerion Therapeutics Inc stock information, including NASDAQ:CYCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYCN stock methods without spending real money on the virtual paper trading platform.